The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The (un)targeted cancer kinome
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B., Eisenhaure, T. M., Luo, B., Grenier, J. K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.040 · Cited by 1,798
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 538
Genetic Progression and the Waiting Time to Cancer
Beerenwinkel, N., Antal, T., Dingli, D., Traulsen, A., Kinzler, K. W., Velculescu, V. E., Vogelstein, B., & Nowak, M. A. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030225 · Cited by 408
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Müller, S., Bullock, A. N., Schwaller, J., Sundström, M., & Knapp, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708800104 · Cited by 359
Self-citationA synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A. N., & Ashworth, A. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.61 · Cited by 322
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
Recognizing and exploiting differences between RNAi and small-molecule inhibitors
Weiss, W. A., Taylor, S. S., & Shokat, K. M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio1207-739 · Cited by 283
NAKANO, H., KOBAYASHI, E., TAKAHASHI, I., TAMAOKI, T., KUZUU, Y., & IBA, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.706 · Cited by 262
Cell regulation: determined to signal discrete cooperation
Gibson, T. J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.06.007 · Cited by 170
Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery
Bamborough, P., Drewry, D., Harper, G., Smith, G. K., & Schneider, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8011036 · Cited by 158
Kinomics: characterizing the therapeutically validated kinase space
Vieth, M., Sutherland, J. J., Robertson, D. H., & Campbell, R. M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03477-x · Cited by 157
Bommi‐Reddy, A., Almeciga, I., Sawyer, J., Geisen, C., Li, W., Harlow, E., Kaelin, W. G., & Grueneberg, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806574105 · Cited by 151
A multidimensional analysis of genes mutated in breast and colorectal cancersPreprint
Lin, J., Gan, C. M., Zhang, X., Jones, S., Sjöblom, T., Wood, L. D., Parsons, D. W., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2007) · Genome Research · doi:10.1101/gr.6431107 · Cited by 146
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1
Hindie, V., Stroba, A., Zhang, H., Lopez-Garcia, L. A., Idrissova, L., Zeuzem, S., Hirschberg, D., Schaeffer, F., Jørgensen, T. J. D., Engel, M., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.208 · Cited by 141
Do molecularly targeted agents in oncology have reduced attrition rates?
Walker, I., & Newell, H. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2758 · Cited by 130
Cancer driver mutations in protein kinase genes
Torkamani, A., Verkhivker, G. M., & Schork, N. J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.11.008 · Cited by 113
Allosteric activation of the protein kinase PDK1 with low molecular weight compounds
Engel, M., Hindie, V., Lopez-Garcia, L. A., Stroba, A., Schaeffer, F., Adrian, I., Imig, J., Idrissova, L., Nastainczyk, W., Zeuzem, S., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601416 · Cited by 110
Cytokine-Induced Signaling Networks Prioritize Dynamic Range over Signal Strength
Janes, K. A., Reinhardt, H. C., & Yaffe, M. B. (2008) · Cell · doi:10.1016/j.cell.2008.08.034 · Cited by 105
Prediction of Cancer Driver Mutations in Protein Kinases
Torkamani, A., & Schork, N. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5283 · Cited by 102
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Lackey, K. E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743156 · Cited by 92
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
Grueneberg, D. A., Degot, S., Pearlberg, J., Li, W., Davies, J. E., Baldwin, A. E., Endege, W. O., Doench, J. G., Sawyer, J., Hu, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808019105 · Cited by 89
Challenges and Opportunities in Defining the Essential Cancer Kinome
Manning, B. D. (2009) · Science Signaling · doi:10.1126/scisignal.263pe15 · Cited by 59
Tecle, H., Shao, J., Li, Y., Kothe, M., Kazmirski, S. L., Penzotti, J. E., Ding, Y., Ohren, J. F., Moshinsky, D., Coli, R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.108 · Cited by 45
Baldwin, A. E., Li, W., Grace, M. R., Pearlberg, J., Harlow, E., Münger, K., & Grueneberg, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806195105 · Cited by 45
Grueneberg, D. A., Li, W., Davies, J. E., Sawyer, J., Pearlberg, J., & Harlow, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806578105 · Cited by 35
Cited by
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
DeepDTA: deep drug–target binding affinity prediction
Öztürk, H., Özgür, A., & Ozkirimli, E. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty593 · Cited by 1,696
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919
Metadata
- Authors
- Fedorov, O., Müller, S., & Knapp, S.
- Venue
- Nature Chemical Biology
- Published
- 2010-03
- Volume
- 6
- Issue
- 3
- Pages
- 166-169
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2042553090
- Cited by
- 292
- References
- 38
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.